Validation of a bowel function diary for assessing opioid-induced constipation

American Journal of Gastroenterology

Volumn 106, Issue 3, 2011, Pages 497-506

  Camilleri, Michael ^a   Rothman, Margaret ^b   Ho, Kai Fai ^c   Etropolski, Mila ^b  

^a Mayo Clinic   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c Department of Clinical Biostatistics   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NARCOTIC ANALGESIC AGENT;

ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; BLOATING; BOWEL FUNCTION DIARY; CHRONIC PAIN; CONSTIPATION; FEMALE; FLATULENCE; HIP OSTEOARTHRITIS; HUMAN; INTESTINE MOTILITY; KNEE OSTEOARTHRITIS; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; SELF REPORT; TEST RETEST RELIABILITY; VALIDATION STUDY; VALIDITY;

ADULT; AGED; ANALGESICS, OPIOID; CHRONIC DISEASE; CONSTIPATION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PAIN; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX;

EID: 79952360501     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.431     Document Type: Article

References (32)

1. Chou R, Fanciullo GJ, Fine PG et al. American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10:113-30.
2. Zhang W, Moskowitz RW, Nuki G et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008;16:137-62. (Pubitemid 351222155)
3. Kalso E, Edwards JE, Moore A et al. Opioids in chronic non-cancer pain: systematic review of Efficacy and safety. Pain 2004;112:372-80. (Pubitemid 39550738)
4. Papagallo M. Incidence, prevalence and management of opioid bowel dysfunction. Am J Surg 2001;182 (Nov Suppl):S11-8.
5. Benyamin R, Trescot AM, Datta S et al. Opioid complications and side effects. Pain Physician 2008;11 (2 Suppl):S105-20. (Pubitemid 351682081)
6. Afilalo M, Etropolski MS, Kuperwasser B et al Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: results of a randomized, double-blind, placebo- and activecontrolled phase 3 study. Clin Drug Invest 2010 30 489-505.
7. Buynak R, Shapiro DY, Okamoto A et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled phase III study. Expert Opin Pharmacother 2010;11:1787-804.
8. Slappendel R, Simpson K, Dubois D et al. Development of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain. Eur J Pain 2006;10:209-17. (Pubitemid 43255207)
9. Sloots CE, Rykx A, Cools M et al. Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Dig Dis Sci 2010;55:2912-21.
10. Frank L, Kleinman L, Farup C et al. Psychometric validation of a constipation symptom assessment questionnaire. Scand J Gastroenterol 1999;34:870-7. (Pubitemid 29470564)
11. U.S. Department of Health and Human Services/Food and Drug Administration . Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. December 2009. [Last accessed 01 June 2010] (Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf).
12. U.S. Department of Health and Human Services/Food and Drug Administration . Guidance for Industry Irritable Bowel Syndrome - Clinical Evaluation of Products for Treatment. March 2010. [Last accessed 01 June 2010] (Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM205269.pdf).
13. Drossman DA. The functional gastrointestinal disorder and the Rome III process. Gastroenterology 2006;130:1377-90.
14. Heaton KW, Ghosh S, Braddon FE. How bad are the symptoms and bowel dysfunction of patients with the irritable bowel syndrome? A prospective, controlled study with emphasis on stool form. Gut 1991;32:73-9.
15. O ' Donnell LJ, Virjee J, Heaton KW. Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate. BMJ 1990;300:439-40. (Pubitemid 20069266)
16. Guy W. ECDEU Assessment Manual for Psychopharmacology. National Institute of Mental Health, US Department of Health, Education and Welfare: Rockville, MD, 1976.
17. Fayers PM, Machin D. Quality of Life: The Assessment, Analysis and Interpretation of Patient-Reported Outcomes, 2nd edn, John Wiley: Chichester, West Sussex, England, 2007.
18. Litwin M. How to Measure Survey Reliability and Validity. The Survey Kit, Vol 7. Sage: Thousand Oaks, CA, 1995.
19. Streiner DL, Norman GR. Health Measurement Scales: A Practical Guide to Th eir Development and Use, 4th edn, Oxford University Press: Cary, NC, 2008.
20. American Educational Research Association, APA, National Research Council on Measurement in Education. Standards for Educational and Psychological Testing. AERA: Washington, DC, 1999.
21. Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989;27:178-89.
22. Cohen J. Statistical Power for the Social Sciences, 2nd edn, Lawrence Earlbaum Associates: Hillsdale, NJ, 1988.
23. Brandt LJ, Prather CM, Quigley EMM et al. Systematic review on the management of chronic constipation in North America. Am J Gastroenterol 2005;100 (S1A):S5-22.
24. Rentz AM, Yu R, M ü ller-Lissner S et al. Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation . J Med Econ 2009;12:371-83.
25. Camilleri M, Kerstens R, Rykx A et al. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008;358:2344-54. (Pubitemid 351749158)
26. Barish CF, Drossman D, Johanson JF et al. Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci 2010;55:1090-7.
27. Lembo AJ, Kurtz CB, Macdougall JE et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology 2010;138:886-95.
28. Degen LP, Phillips SF. How well does stool form reflect colonic transit? Gut 1996;39:109-13. (Pubitemid 26239116)
29. Kaufman PN, Krevsky B, Malmud LS et al. Role of opiate receptors in the regulation of colonic transit. Gastroenterology 1988;94:1351-6.
30. Wirz S, Klaschik E. Management of constipation in palliative care patients undergoing opioid therapy: is polyethylene glycol an option? Am J Hosp Palliat Care 2005;22:375-81. (Pubitemid 41432865)
31. Thomas J, Karver S, Cooney GA et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008;358:2332-43. (Pubitemid 351749157)
32. Trentacosti AM, He R, Burke LB et al. Evolution of clinical trials for irritable bowel syndrome: issues in end points and study design. Am J Gastroenterol 2010;105:731-5.